Israeli - Kiebrania - Ministry of Health

inovamed ltd - finasteride - film coated tablets - finasteride - for the treatment and control of benign prostatic hyperplasia (bph) and for the prevention of urologic events to reduce the risk of acute urinary retention.reduce the risk of surgery including transurethral resection of the prostate (turp) and prostatectomy. this product causes regression of the enlarged prostate, improves urinary flow and improves the symptoms assocciated with bph. patients with an enlarged prostate are the appropriate candidates for therapy with this product.

Israeli - Kiebrania - Ministry of Health

novartis pharma services ag - tetracosactide hexaacetate 1 mg/ml - suspension for injection - tetracosactide - collagen diseases, neurological diseases, chronic skin disorders.

Israeli - Kiebrania - Ministry of Health

ferring pharmaceuticals ltd - desmopressin acetate - תמיסה להזרקה - desmopressin acetate 15 mcg/ml - desmopressin - desmopressin - shortening/normalization/ control of bleeding in uremia, liver cirrhoses, congenital or drug induced thrombocyte dysfunction and of unknown aetiology before surgery. mild haemophilia a and mild von willebrands except type iib.

Israeli - Kiebrania - Ministry of Health

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

Israeli - Kiebrania - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Israeli - Kiebrania - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Israeli - Kiebrania - Ministry of Health

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

Israeli - Kiebrania - Ministry of Health

sanofi - aventis israel ltd - lenograstim 33.6 miu/ml - lyophilized powder for injection - lenograstim - - reduction in duration of neutropenia and associated complications in patients undergoing bone marrow transplantation or cytotoxic chemotherapy associated with a febrile neutropenia. - autologous mobilization of peripheral blood progenitor cells. as an adjunct to allogenic mobilization of peripheral blood progenitor cells (pbpcs).

Israeli - Kiebrania - Ministry of Health

sanofi - aventis israel ltd - plerixafor 24 mg / 1.2 ml - solution for injection - plerixafor - mozobil is indicated in combination with g-csf to enhance mobilisation of haematopietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma .

Israeli - Kiebrania - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.